CAJ | 학술논문

目的：观察腹型肥胖的2型糖尿病患者应用利拉鲁肽治疗的疗效及其安全性。方法筛选20例符合入选标准的腹型肥胖2型糖尿病患者,在原有降糖药物基础上,加用利拉鲁肽0.6~1.8 mg皮下注射,1次/d。治疗随访观察12周,比较治疗前后空腹血糖(FPG)、餐后2 h血糖(2 hPG)、空腹及餐后2 h胰岛素及C肽、糖化血红蛋白(HbA1c)、体重指数(BMI)、腰围、血压、血脂的变化情况。观察并记录其不良反应。结果对采用利拉鲁肽治疗患者前后的空腹血糖、餐后2h血糖、糖化血红蛋白、体重、BMI、腰围、HOMA-β及HOMA-IR指数相互比较,其差异有统计学意义( P<0.05)。观察到有少数患者出现不良反应,但均能耐受治疗。结论在原有口服降糖药物基础上加用利拉鲁肽能有效降低血糖,显著降低患者体重,并能改善胰岛β细胞功能,降低血脂、血压,且发生低血糖的风险低,是2型糖尿病患者治疗的新选择。
목적：관찰복형비반적2형당뇨병환자응용리랍로태치료적료효급기안전성。방법사선20례부합입선표준적복형비반2형당뇨병환자,재원유강당약물기출상,가용리랍로태0.6~1.8 mg피하주사,1차/d。치료수방관찰12주,비교치료전후공복혈당(FPG)、찬후2 h혈당(2 hPG)、공복급찬후2 h이도소급C태、당화혈홍단백(HbA1c)、체중지수(BMI)、요위、혈압、혈지적변화정황。관찰병기록기불량반응。결과대채용리랍로태치료환자전후적공복혈당、찬후2h혈당、당화혈홍단백、체중、BMI、요위、HOMA-β급HOMA-IR지수상호비교,기차이유통계학의의( P<0.05)。관찰도유소수환자출현불량반응,단균능내수치료。결론재원유구복강당약물기출상가용리랍로태능유효강저혈당,현저강저환자체중,병능개선이도β세포공능,강저혈지、혈압,차발생저혈당적풍험저,시2형당뇨병환자치료적신선택。
Objective To observe the efficacy and safety of liraglutide in the treatment of abdominal obesity patient with type 2 diabetics. Methods 20 cases of abdominal obesity patients with type 2 diabetics, based on the original antidiabetic drugs, the addition of lirarupeptide 0.6~1.8 mg subcutaneous injection, 1 time/d. Treatment were followed up for 12 weeks,compared the fasting blood glucose(FPG),2 h postprandial blood glucose(2 HPG), fasting and 2 h postprandial insulin and C peptide,glycosylated hemoglobin(HbA1c), body mass index(BMI), waist circumference, blood pressure,blood lipid changes. Observe and record the adverse reactions. Results Patients with liraglutide treatment before and after the fasting blood glucose, postprandial 2 hours blood glucose, glycosylated hemoglobin, weight, BMI, waist circumference, HOMA-βand HOMA-IR index were compared, and the differences were statistically significant(P<0.05). Observed a few adverse reactions in patients with, but tolerated treatment. Conclusion Oral hypoglycemic drugs plus the liraglutide can effectively reduce the blood sugar, significantly reduced in patients with body weight, and can improve the function of islet beta cells, reduce blood fat, blood pressure, and low risk of hypoglycemia, is a new treatment option for patients with type 2 diabetes.